BioWorld MedTech

Sep. 17, 2018

Vital Therapies shares plunge again as company ponders future

HAMBURG, Germany – Shares of Vital Therapies Inc. (NASDAQ:VTL), which plunged on Sept. 12 after bad news about its ELAD liver therapy (extracorporeal liver-assist device), were hammered yet again, closing at $0.35 on Sept. 14 as the company ponders its future. Read More

Philips partners with IoT startup Integron to provide connected health management

Thompson: timing, not speed, the story for Apple de novos

Researchers win grant to develop radiotracer dose-on-demand capability

Neuroqore developing device to take the shock out of treating depression

Other news to note

Daily M&A

Financings

Appointments and advancements

Product briefs

Regulatory front

BioWorld MedTech's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

TREM2 agonists detailed in Pfizer patent

BioWorld Science

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma

BioWorld Science

Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...

Female uterus and ovaries on abstract scientific background

Menstrual ‘footprints’ may act as broad personal health markers

BioWorld

WAVES, an algorithm designed to extract menstrual-cycle metrics from physiological signals such as basal body temperature, which oscillates with sex hormones,...